This filing is procedural and does not change the near-term thesis. The key catalyst remains the Treeline merger closing, which is a condition to this divestiture. Monitor for LAB shareholder vote on both the mass cytometry sale and the Treeline merger, and for any regulatory updates. The modest $5M base consideration is not material to LAB's valuation.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 29 $0.8739entry
- T+1 · 4mo ago +2.68%α +1.00% · $0.8973
- T+5 · 3mo ago −10.28%α −15.80% · $0.7841
- T+20 · 3mo ago −25.41%α −30.43% · $0.6518
- T+60 · 26d ago −27.27%α −32.00% · $0.6356
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Standard BioTools (LAB) filed an 8-K/A on July 29, 2026, attaching the full Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc., as previously announced on July 28, 2026. The deal includes a $5M base purchase price (paid via promissory note) plus up to $5M in contingent additional consideration tied to a future Qualifying Exit by Multiplex Bio. The transaction is a procedural step in LAB's broader restructuring ahead of its transformative reverse merger with Treeline Biosciences, and its closing is conditioned on the Treeline merger closing substantially concurrently.
Key Financial Metrics
Key Facts
- LAB sells its mass cytometry business (CyTOF, Hyperion, Maxpar, Theia platforms) to Multiplex Bio Inc.
- Base purchase price of $5,000,000, paid via a promissory note (Base Seller Note), subject to working capital and other adjustments.
- Additional contingent consideration of $5,000,000 if Multiplex Bio achieves a Qualifying Exit (e.g., sale, IPO) within 10 years.
- Target Working Capital set at $4,727,000.
- Seller termination fee of $1,000,000.
- Outside Date for closing is June 30, 2027, with automatic extensions for stockholder approval or antitrust issues.
- Closing is conditioned on LAB stockholder approval and the concurrent closing of the Treeline merger.
- Non-compete restricts LAB from engaging in mass cytometry business for 3 years post-closing.
Financial Impact
Base purchase price of $5M (promissory note) plus up to $5M contingent additional consideration; deal is small relative to LAB's $311M market cap and the $2.5B Treeline merger.
Risk Factors
- Failure to obtain LAB stockholder approval for the mass cytometry sale or the Treeline merger.
- Failure to close the Treeline merger, which would prevent this divestiture from closing.
- Potential competing offers or regulatory delays extending beyond the Outside Date.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001140361-26-029965 |
| Document: 0001140361-26-029965-index-headers.html | 0001140361-26-029965 |
| Document: 0001140361-26-029965-index.html | 0001140361-26-029965 |
| Document: 0001140361-26-029965.txt | 0001140361-26-029965 |
Track record
23 reports on LAB
7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today 425 Neutral 4/10 Entry price pending
- Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
- Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
- Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
- Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers